Universe Pharmaceuticals (NASDAQ:UPC) Raised to “Hold” at Wall Street Zen

Universe Pharmaceuticals (NASDAQ:UPC) was upgraded by investment analysts at Wall Street Zen to a “hold” rating in a research note issued on Saturday.

Separately, Weiss Ratings raised Universe Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, July 29th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company presently has a consensus rating of “Sell”.

Universe Pharmaceuticals Price Performance

Shares of UPC opened at $4.90 on Friday. Universe Pharmaceuticals has a 1-year low of $2.00 and a 1-year high of $17.96. The firm has a 50-day simple moving average of $5.08 and a two-hundred day simple moving average of $3.67. The company has a current ratio of 4.05, a quick ratio of 3.90 and a debt-to-equity ratio of 0.04.

Universe Pharmaceuticals (NASDAQ:UPC) last released its quarterly earnings results on Wednesday, July 29th. The company reported ($1.38) earnings per share (EPS) for the quarter. The firm had revenue of $4.52 million for the quarter.

Universe Pharmaceuticals Company Profile

Universe Pharmaceuticals, Inc is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics for ocular diseases. The company’s primary research efforts center on small-molecule compounds designed to address unmet needs in glaucoma, ocular hypertension and post-surgical ocular inflammation. By leveraging targeted enzyme inhibition and proprietary formulation technologies, Universe aims to bring forward topically administered medications that combine efficacy with an improved safety profile versus existing treatments.

The company’s lead candidate, UPC-1001, has been advanced into clinical trials for the treatment of open-angle glaucoma and ocular hypertension, where it seeks to lower intraocular pressure through a unique mechanism of action.